|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Orditura M, Galizia G, Sforza V,
Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J,
Savastano B, Mabilia A, et al: Treatment of gastric cancer. World J
Gastroenterol. 20:1635–1649. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lippert TH, Ruoff HJ and Volm M: Intrinsic
and acquired drug resistance in malignant tumors. The main reason
for therapeutic failure. Arzneimittelforschung. 58:261–264.
2008.PubMed/NCBI
|
|
4
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Longley DB and Johnston PG: Molecular
mechanisms of drug resistance. J Pathol. 205:275–292. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nakagawa Y, Sedukhina AS, Okamoto N,
Nagasawa S, Suzuki N, Ohta T, Hattori H, Roche-Molina M, Narváez
AJ, Jeyasekharan AD, et al: NF-κB signaling mediates acquired
resistance after PARP inhibition. Oncotarget. 6:3825–3839. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Halilovic E, She QB, Ye Q, Pagliarini R,
Sellers WR, Solit DB and Rosen N: PIK3CA mutation uncouples tumor
growth and cyclin D1 regulation from MEK/ERK and mutant KRAS
signaling. Cancer Res. 70:6804–6814. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Michaelis M, Rothweiler F, Barth S, Cinatl
J, van Rikxoort M, Löschmann N, Voges Y, Breitling R, von Deimling
A, Rödel F, et al: Adaptation of cancer cells from different
entities to the MDM2 inhibitor nutlin-3 results in the emergence of
p53-mutated multi-drug-resistant cancer cells. Cell Death Dis.
2:e2432011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin X, Zhang X, Wang Q, Li J, Zhang P,
Zhao M and Li X: Perifosine downregulates MDR1 gene expression and
reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-κB
signaling pathway in a human breast cancer cell line. Neoplasma.
59:248–256. 2012. View Article : Google Scholar
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu
G, Zhao R, Huang H, Wang X, Qiao Y, et al: MiR-152 and miR-185
co-contribute to ovarian cancer cells cisplatin sensitivity by
targeting DNMT1 directly: A novel epigenetic therapy independent of
decitabine. Oncogene. 33:378–386. 2014. View Article : Google Scholar
|
|
12
|
Shang Y, Zhang Z, Liu Z, Feng B, Ren G, Li
K, Zhou L, Sun Y, Li M, Zhou J, et al: MiR-508–5p regulates
multidrug resistance of gastric cancer by targeting ABCB1 and
ZNRD1. Oncogene. 33:3267–3276. 2014. View Article : Google Scholar
|
|
13
|
Sui C, Meng F, Li Y and Jiang Y: MiR-148b
reverses cisplatin-resistance in non-small cell cancer cells via
negatively regulating DNA (cytosine-5)-methyltransferase 1 (DNMT1)
expression. J Transl Med. 13:1322015. View Article : Google Scholar
|
|
14
|
Fang L, Li H, Wang L, Hu J, Jin T, Wang J
and Yang BB: MicroRNA-17–5p promotes chemotherapeutic drug
resistance and tumour metastasis of colorectal cancer by repressing
PTEN expression. Oncotarget. 5:2974–2987. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
van Jaarsveld MT, Helleman J, Boersma AW,
van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, Mathijssen RH,
Berns EM, Verweij J, et al: MiR-141 regulates KEAP1 and modulates
cisplatin sensitivity in ovarian cancer cells. Oncogene.
32:4284–4293. 2013. View Article : Google Scholar
|
|
16
|
Eberle KE, Sansing HA, Szaniszlo P, Resto
VA and Berrier AL: Carcinoma matrix controls resistance to
cisplatin through talin regulation of NF-kB. PLoS One.
6:e214962011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J,
Jiang B, Shu Y and Liu P: MiR-200bc/429 cluster modulates multidrug
resistance of human cancer cell lines by targeting BCL2 and XIAP.
Cancer Chemother Pharmacol. 69:723–731. 2012. View Article : Google Scholar
|
|
18
|
Zhu W, Shan X, Wang T, Shu Y and Liu P:
MiR-181b modulates multidrug resistance by targeting BCL2 in human
cancer cell lines. Int J Cancer. 127:2520–2529. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao DS, Chen Y, Jiang H, Lu JP, Zhang G,
Geng J, Zhang Q, Shen JH, Zhou X, Zhu W and Shan QJ: Serum miR-210
and miR-30a expressions tend to revert to fetal levels in Chinese
adult patients with chronic heart failure. Cardiovasc Pathol.
22:444–450. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou X, Zhu W, Li H, Wen W, Cheng W, Wang
F, Wu Y, Qi L, Fan Y, Chen Y, et al: Diagnostic value of a plasma
microRNA signature in gastric cancer: A microRNA expression
analysis. Sci Rep. 5:112512015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bratthauer GL: The avidin-biotin complex
(ABC) method and other avidin-biotin binding methods. Methods Mol
Biol. 588:257–270. 2010. View Article : Google Scholar
|
|
22
|
Zhu DX, Zhu W, Fang C, Fan L, Zou ZJ, Wang
YH, Liu P, Hong M, Miao KR, Liu P, et al: MiR-181a/b significantly
enhances drug sensitivity in chronic lymphocytic leukemia cells via
targeting multiple anti-apoptosis genes. Carcinogenesis.
33:1294–1301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao S, Yao D, Chen J, Ding N and Ren F:
MiR-20a promotes cervical cancer proliferation and metastasis in
vitro and in vivo. PLoS One. 10:e01209052015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fan X, Liu Y, Jiang J, Ma Z, Wu H, Liu T,
Liu M, Li X and Tang H: MiR-20a promotes proliferation and invasion
by targeting APP in human ovarian cancer cells. Acta Biochim
Biophys Sin (Shanghai). 42:318–324. 2010. View Article : Google Scholar
|
|
25
|
Huang G, Nishimoto K, Zhou Z, Hughes D and
Kleinerman ES: MiR-20a encoded by the miR-17–92 cluster increases
the metastatic potential of osteosarcoma cells by regulating Fas
expression. Cancer Res. 72:908–916. 2012. View Article : Google Scholar
|
|
26
|
Xiong Y, Zhang L and Kebebew E: MiR-20a is
upregulated in anaplastic thyroid cancer and targets LIMK1. PLoS
One. 9:e961032014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zeng X, Xiang J, Wu M, Xiong W, Tang H,
Deng M, Li X, Liao Q, Su B, Luo Z, et al: Circulating miR-17,
miR-20a, miR-29c and miR-223 combined as non-invasive biomarkers in
nasopharyngeal carcinoma. PLoS One. 7:e463672012. View Article : Google Scholar
|
|
28
|
Li X, Zhang Z, Yu M, Li L, Du G, Xiao W
and Yang H: Involvement of miR-20a in promoting gastric cancer
progression by targeting early growth response 2 (EGR2). Int J Mol
Sci. 14:16226–16239. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chai H, Liu M, Tian R, Li X and Tang H:
MiR-20a targets BNIP2 and contributes chemotherapeutic resistance
in colorectal adeno-carcinoma SW480 and SW620 cell lines. Acta
Biochim Biophys Sin (Shanghai). 43:217–225. 2011. View Article : Google Scholar
|
|
30
|
Wang ZH, Chen H, Guo HC, Tong HF, Liu JX,
Wei WT, Tan W, Ni ZL, Liu HB and Lin SZ: Enhanced antitumor
efficacy by the combination of emodin and gemcitabine against human
pancreatic cancer cells via downregulation of the expression of
XIAP in vitro and in vivo. Int J Oncol. 39:1123–1131.
2011.PubMed/NCBI
|
|
31
|
Li F and Sethi G: Targeting transcription
factor NF-kappaB to overcome chemoresistance and radioresistance in
cancer therapy. Biochim Biophys Acta. 1805:167–180. 2010.PubMed/NCBI
|
|
32
|
Jono H, Lim JH, Chen LF, Xu H, Trompouki
E, Pan ZK, Mosialos G and Li JD: NF-kappaB is essential for
induction of CYLD, the negative regulator of NF-kappaB: Evidence
for a novel inducible autoregulatory feedback pathway. J Biol Chem.
279:36171–36174. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Regamey A, Hohl D, Liu JW, Roger T,
Kogerman P, Toftgard R and Huber M: The tumor suppressor CYLD
interacts with TRIP and regulates negatively nuclear factor kappaB
activation by tumor necrosis factor. J Exp Med. 198:1959–1964.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kovalenko A, Chable-Bessia C, Cantarella
G, Israël A, Wallach D and Courtois G: The tumour suppressor CYLD
negatively regulates NF-kappaB signalling by deubiquitination.
Nature. 424:801–805. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Brummelkamp TR, Nijman SM, Dirac AM and
Bernards R: Loss of the cylindromatosis tumour suppressor inhibits
apoptosis by activating NF-kappaB. Nature. 424:797–801. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xia JT, Chen LZ, Jian WH, Wang KB, Yang
YZ, He WL, He YL, Chen D and Li W: MicroRNA-362 induces cell
proliferation and apoptosis resistance in gastric cancer by
activation of NF-κB signaling. J Transl Med. 12:332014. View Article : Google Scholar
|
|
37
|
Manu KA, Shanmugam MK, Ramachandran L, Li
F, Fong CW, Kumar AP, Tan P and Sethi G: First evidence that
γ-tocotrienol inhibits the growth of human gastric cancer and
chemosensitizes it to capecitabine in a xenograft mouse model
through the modulation of NF-κB pathway. Clin Cancer Res.
18:2220–2229. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vucic D and Fairbrother WJ: The inhibitor
of apoptosis proteins as therapeutic targets in cancer. Clin Cancer
Res. 13:5995–6000. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou R, Hu G, Gong AY and Chen XM: Binding
of NF-kappaB p65 subunit to the promoter elements is involved in
LPS-induced transactivation of miRNA genes in human biliary
epithelial cells. Nucleic Acids Res. 38:3222–3232. 2010. View Article : Google Scholar : PubMed/NCBI
|
